Updated:
Origincell Technology Group
Qu Jianguo launched Origincell Technology Group in July 2014 with Canature Health (SZ:300272), committing an initial RMB 1.5 billion. The firm’s headquarters...
Origincell Technology Group
Qu Jianguo launched Origincell Technology Group in July 2014 with Canature Health (SZ:300272), committing an initial RMB 1.5 billion. The firm’s headquarters sit on an 80-mu campus in Shanghai’s Zhangjiang Science City, spanning three specialized parks — Origincell Industrial Park, Origincell Science Park, and Origincell Pharmaceutical Park. Qu brought three prior decades of public-company founding experience across the automotive and water-treatment sectors, but Origincell marks his direct pivot into cellular infrastructure. The group pursues hard-asset deployment in automated biobanking: its flagship Zhangjiang facility runs an unmanned 5G cell bank designed for 10-million-sample capacity. Investments layer across the cell-based economy: third-party cell storage via subsidiary Origincell Bio, automated storage equipment manufacturing, immune-cell therapy development under Yuantian Bio, a laboratory-animal CRO platform through Laisenyan Life Sciences, and cell-derived skincare via Jiyuan Meiye. Project partnerships extend from a Washington University cryobiology collaboration to industry pilots with China Telecom, ABB, and the Shanghai First People’s Hospital for clinical cell-therapy translation. Origincell operates three Shanghai parks and supports a growing compliance footprint — its subsidiary Yuantian Bio received an IND clearance from China’s NMPA for an MSC therapy in October 2024 (per the firm, October 2024). In April 2026, the group launched an additional cell facility in Fujian province with Zhangzhou’s Jiulongjiang Group, signaling an infrastructure-replication model beyond Shanghai. The firm participates in the International Society for Biological and Environmental Repositories and maintains three philanthropic foundations, including the Shanghai Jianguo Public Foundation. Unlike a typical corporate venture arm, Origincell owns and operates the physical cleanrooms, cryogenic equipment, and preclinical service lines that biotech startups depend on. This infrastructure-operator posture — not minority LP positions — determines its allocation logic, making it a site-selector and operating partner for cell-industry initiatives in China’s municipal-level health plans.
General information
Firm type
Corporate Investor
Year founded
2014
AUM
Undisclosed
Location
Region
Asia
Country
China
City
Shanghai
Corporate office
Zhangjiang Science City, Pudong New Area, Shanghai, China
Principals
Qu Jianguo
Founder and Chairman
Sector focus
Frequently asked questions
How does Origincell Technology Group deploy its capital?
Origincell is an operator-investor, not a fund. It commits balance-sheet capital into wholly owned subsidiaries and project partnerships that build physical cell-biology infrastructure: automated biobanks, GMP-grade cell preparation facilities, and laboratory-animal CRO platforms. The group’s disclosed deployment includes an initial RMB 1.5 billion into three Shanghai industrial parks (per the firm, 2014) and later co-development agreements with municipalities such as Kunming and Zhangzhou.
What is the relationship between Origincell Technology Group and Canature Health?
Canature Health (SZ:300272), founded earlier by Qu Jianguo, is a co-founder and listed backer of Origincell Technology Group. The corporate structure treats Origincell as a separately governed entity under Qu’s leadership, with Canature’s home-water-treatment business providing initial capital but operating independently from the cell-technology group’s subsidiaries.
What is the unmanned 5G cell bank in Zhangjiang?
The facility is Origincell’s operational benchmark — a fully automated, human-free cell-storage warehouse leveraging 5G-enabled robotics and intelligent scheduling. Built as a demonstration plant within Origincell’s headquarters campus, it targets a capacity of 10 million samples and anchors the group’s thesis that cryogenic infrastructure, not just biotech equity, is the bottleneck in China’s cell-therapy supply chain.
Does Origincell operate as a single-family office or a corporate venture arm?
It functions as a corporate investor with an infrastructure-operator model. Qu Jianguo is the controlling founder, but the group’s capital flows through operating subsidiaries — Origincell Bio, Yuantian Bio, Jiyuan Meiye, Laisenyan Life Sciences — and project-level government collaborations, rather than through a family-office portfolio of external fund commitments.
Which sectors does Origincell explicitly avoid?
The group’s capital stays within the cell economy defined by its operational stack: cryogenic storage, cell manufacturing, therapy development, laboratory services, and cell-based skincare. There is no disclosed interest in generic life-science VC, data-only digital health, or non-cell biopharma, which aligns with its model of owning the infrastructure layer rather than making passive LP commitments across an undifferentiated health-tech mandate.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on investors?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: